Precision Medicine in Gastrointestinal Neoplasms

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: 25 January 2027 | Viewed by 733

Editors


E-Mail
Guest Editor
Department of General and Digestive Surgery, Torrecardenas University Hospital, Almería, Spain
Interests: peritoneal oncology; digestive cancers

E-Mail Website
Guest Editor
1. Medical and Radiotherapeutic Unit, University Hospital Virgen de las Nieves, Avenida de la Ilustración, 114-18016 Granada, Spain
2. Liquid Biopsy and Cancer Interception Group, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain
Interests: liquid biopsy; circulating tumor cells (CTCs); platelets educated tumor (PETs); extracellular vesicles (EVs); circulating tumor nucleic acids (ctNA); cancer interception (CI)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Precision medicine in gastrointestinal malignancies represents an innovative and highly specialized approach to cancer treatment. This paradigm focuses on personalizing treatment based on the specific genetic and molecular characteristics of each patient's tumor, as well as other individual factors.

The focus of this Special Issue is on, but not limited to, the following:

  1. Tumor genomics or DNA sequencing
  2. Biomarkers: predictive or prognostic
  3. Targeted therapies
  4. Immunotherapy.

Moreover, some challenges we are currently facing that should be clarified in the near future include the following:

  1. Accessibility and Cost: Genetic testing and targeted therapies can be expensive and are not always covered by insurance.
  2. Continuous Research: Need for clinical studies that validate new therapies and combinations.
  3. Liquid Biopsies: Development of noninvasive methods for monitoring tumor evolution and response to treatment.

In summary, precision medicine in gastrointestinal malignancies promises to significantly improve treatment outcomes by tailoring interventions to each patient's unique characteristics, thereby reducing side effects and increasing treatment efficacy. This Special Issue, entitled “Precision Medicine in Gastrointestinal Neoplasms”, is a great opportunity for teams working on these topics to present their studies, their experiences, and their results. It is undoubted that this Special Issue will contribute to generating a greater degree of knowledge about this exciting topic.

Dr. Juan Torres-Melero
Dr. María Jose Serrano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • digestive cancers
  • molecular biology
  • gastrointestinal cancers
  • gynecological cancers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1505 KB  
Review
From Anatomical Staging to Precision Prognostication: Evolution of Gallbladder Cancer Staging Across AJCC Editions and the 2025 UICC TNM Update
by Tianyi Shen, Nicholas Kai Yi Tan, Wen Xuan Chew, Matthias Yi Quan Liau, Vor Luvira, Vinay K. Kapoor, Orestis Ioannidis and Vishal G. Shelat
J. Pers. Med. 2026, 16(8), 396; https://doi.org/10.3390/jpm16080396 - 24 Jul 2026
Abstract
Gallbladder cancer (GBC) is the most common biliary tract malignancy and is among the most lethal gastrointestinal cancers. Since its inclusion in cancer staging manuals, the GBC Tumour–Node–Metastasis (TNM) classification has undergone repeated revisions intended to improve anatomical precision and prognostic discrimination. This [...] Read more.
Gallbladder cancer (GBC) is the most common biliary tract malignancy and is among the most lethal gastrointestinal cancers. Since its inclusion in cancer staging manuals, the GBC Tumour–Node–Metastasis (TNM) classification has undergone repeated revisions intended to improve anatomical precision and prognostic discrimination. This narrative review traces the evolution of GBC staging across AJCC editions and the 2025 UICC TNM update and critically examines whether these refinements have translated into clinically meaningful risk stratification. In the 2025 UICC TNM 9 grouping, Stage IA corresponds to T1aN0M0 and Stage IB to T1bN0M0, while T2aN0M0 and T2bN0M0 remain Stage IIA and IIB, respectively. Structured literature searches were performed to identify historical staging documents, population-based analyses, validation studies, and prognostic reports relevant to stage migration, survival discrimination, and emerging staging modifiers. Successive changes, including T-category refinement and the transition from nodal location to nodal burden, have improved anatomical resolution. However, available validation studies suggest that gains in overall prognostic performance remain modest, with reported concordance indices often remaining near 0.66. Contemporary evidence increasingly shows that tumour location, adequacy of lymphadenectomy, number of positive lymph nodes, lymph node ratio, log odds of positive lymph nodes, obstructive jaundice, residual disease status, and selected molecular alterations may capture inter-patient heterogeneity beyond anatomy alone. Future staging refinement should therefore preserve TNM as a common anatomical language while developing validated parallel modifiers that support more individualized prognostication and treatment selection. Full article
(This article belongs to the Special Issue Precision Medicine in Gastrointestinal Neoplasms)
Show Figures

Figure 1

Back to TopTop